Vicarious Surgical Partners with UMass Memorial Medical Center
Vicarious Surgical Inc., a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has signed an agreement with...
Category : Healthcare and Pharmaceutical
Modalis Finalist in XPRIZE Healthspan FSHD Prize, Wins Funds
Modalis Therapeutics Corporation, a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenome editing technology, announced its recognition...
APHINITY Data: Perjeta Cuts Death Risk by 17% in HER2+ Breast Cancer
– Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy – – 21% reduction in...
CARsgen Announces Positive Data for Allogeneic BCMA CAR-T CT0596
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces preliminary clinical data for CT0596, an allogeneic BCMA-targeted...
Alphyn Doses First Patients in CLEAR-AD1 Phase 2b Trial
Zabalafin Hydrogel first topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection Alphyn GmbH,...
VUNO’s AI Cardiac Arrest Risk System Gets CE MDR & UKCA
Early Regulatory Approval Accelerates Expansion Plans in Europe and the Middle East VUNO, a leading South Korean medical AI company, announced today that its flagship AI-powered cardiac arrest...
Prof. Mike Chan’s Vision Validated by Landmark Human Cytology Study
A groundbreaking international study has mapped over 400 distinct human cell types, providing powerful validation for Prof. Mike Chan’s longstanding vision of organ-specific, cell-specific regenerative medicine. This...
Disitamab Vedotin Phase 3 Trial Hits PFS & OS Endpoints
RemeGen Co., Ltd. announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希®), the first domestically approved antibody-drug...
OmniAb Introduces the xPloration® Partner Access Program
High-Throughput Single B-Cell Screening Platform Now Available for Purchase by OmniAb’s Partners for Use in Their Own Laboratories OmniAb, Inc. (NASDAQ: OABI) today introduced the launch...
Northwell Health Awards $1.3M to Fund Employee Health Innovations
2025 Innovation Challenge winners showcased ideas to tackle minimally invasive gynecological surgery, pediatric sleep apnea and an AI-supported radiology platform Three employee-led projects at Northwell Health,...
Zydus Gets USFDA Approval for Generic Glatiramer Acetate Injection
Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL,...
AriBio and Fujirebio Complete Sample Set for Alzheimer’s Biomarkers
Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective sample acquisition as part of the...
Sirius Therapeutics Raises $50M for siRNA Cardiometabolic Therapy
Sirius Therapeutics today announced that it has successfully completed nearly $50 million Series B2 financing to advance clinical development of the Company’s novel siRNA therapeutics...
LifeSpeak Promotes Holistic Employee Wellbeing for Mental Health Month
In honor of Mental Health Awareness Month, LifeSpeak Inc. outlines five actionable strategies to help employers meet the growing demand for connected mental and physical...
Hardenbergh, Sentact & Preverity Merge to Lead in Patient Safety
Combined Company to Unify Under the Sentact Brand The Hardenbergh Group, a leading provider of credentialing, physician peer review and consulting services, announced today its...